, Volume 45, Issue 4, pp 337–344 | Cite as

Exercise and Zoledronic Acid on Lipid Profile and Bone Remodeling in Ovariectomized Rats: a Paradoxical Negative Association?

  • E. Lespessailles
  • C. Jaffré
  • G. Y. RochefortEmail author
  • E. Dolléans
  • C. L. Benhamou
  • D. Courteix
Original Article


Exercise (EXE) and amino-bisphosphonates (BP) are both considered as useful strategies in the prevention of post-menopausal bone loss. Exercise reduces lipid levels, and BP may induce increase in high-density lipoprotein cholesterol (HDL-C). We hypothesized that combined effects of BP and exercise would produce a better improvement of lipid profile. We studied the specific and combined effects of zoledronic acid (Z) and EXE on lipid profile and bone remodeling in mature ovariectomized (OVX) rats. Six-month old female rats were randomly assigned to either a sham-ovx group (n = 12) or one of four OVX groups (n = 12): vehicle-treated sedentary (OVX); OVX + EXE (OVX-E, running on a treadmill for 12 weeks); OVX + Z (20 μg/kg, i.v.), (OVX-Z); OVX + Z+EXE (OVX-ZE). Total cholesterol (TC), HDL-C and bone remodeling markers were measured at baseline and at the end of the study. We demonstrated that both Z and EXE prevented the increase in bone resorption resulting from OVX, and individually improved the atherosclerotic risk index. Therapy with Z resulted in significant increase (39.00 ± 0.03 vs. 53.6 ± 0.01 mg/dl; +37.4%, P < 0.05) in serum concentration of HDL-C and a non significant decrease in TC (135.30 ± 0.03 vs. 144.80 ± 0.05 mg/dl; −5.8%) in the OVX-Z group compared to the OVX group. Post-menopausal women have elevated risk of CVD and bone resorption, hence, these data ultimately demonstrate (except for the elevated ratio in the combined group) that exercise and zoledronic acid are useful in minimizing the impact of these two processes in women and the combination of the two may be clinically relevant.


Lipid metabolism Atherosclerosis 





Body weight


C terminal collagen cross-links




Fat mass


Farnesyl pyrophosphate synthetase


High-density lipoprotein cholesterol


Hormonal-replacement therapy


Lean body mass


Low-density lipoprotein cholesterol






Ovariectomized + Exercise trained animal


Ovariectomized + Zoledronic acid treated animal


Ovariectomized + Zoledronic acid treated + Exercise trained animal


Parathyroid hormone


Sham-operated animal


Total cholesterol


Total serum cholesterol


Tumor necrosis factor alpha


Uncoupling index


Whole body


Whole body bone mineral content


Whole body bone mineral density


Zoledronic acid



E. Lespessailles was the recipient of a fellowship research grant from Novartis.

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.


  1. 1.
    Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026CrossRefPubMedGoogle Scholar
  2. 2.
    Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100CrossRefPubMedGoogle Scholar
  3. 3.
    Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–584CrossRefPubMedGoogle Scholar
  4. 4.
    Ciosek CP Jr, Magnin DR, Harrity TW, Logan JV, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM et al (1993) Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268:24832–24837PubMedGoogle Scholar
  5. 5.
    Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, Avanzati A, Franci B, Marchini E, Tozzi M, Campagna MS, Nuti R, Lauria F, Martini G (2008) The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 82:258–262CrossRefPubMedGoogle Scholar
  6. 6.
    Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, Wells G, Tugwell P, Cranney A (2002) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333Google Scholar
  7. 7.
    Kelley GA, Kelley KS (2008) Efficacy of aerobic exercise on coronary heart disease risk factors. Prev Cardiol 11:71–75PubMedGoogle Scholar
  8. 8.
    Kelley GA, Kelley KS, Tran ZV (2005) Walking and non-HDL-C in adults: a meta-analysis of randomized controlled trials. Prev Cardiol 8:102–107CrossRefPubMedGoogle Scholar
  9. 9.
    Vasankari TJ, Kujala UM, Vasankari TM, Ahotupa M (1998) Reduced oxidized LDL levels after a 10-month EX program. Med Sci Sports Exerc 30:1496–1501CrossRefPubMedGoogle Scholar
  10. 10.
    Puglisi MJ, Vaishnav U, Shrestha S, Torres-Gonzalez M, Wood RJ, Volek JS, Fernandez ML (2008) Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids Health Dis 7:14PubMedGoogle Scholar
  11. 11.
    Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465–473CrossRefPubMedGoogle Scholar
  12. 12.
    Coxon FP, Helfrich MH, Van’t Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467–1476CrossRefPubMedGoogle Scholar
  13. 13.
    Boppart MD, Kimmel DB, Yee JA, Cullen DM (1998) Time course of osteoblast appearance after in vivo mechanical loading. Bone 23:409–415CrossRefPubMedGoogle Scholar
  14. 14.
    Pead MJ, Skerry TM, Lanyon LE (1988) Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J Bone Miner Res 3:647–656CrossRefPubMedGoogle Scholar
  15. 15.
    Skerry TM, Bitensky L, Chayen J, Lanyon LE (1989) Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 4:783–788CrossRefPubMedGoogle Scholar
  16. 16.
    Wronski TJ, Schenck PA, Cintron M, Walsh CC (1987) Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 40:155–159CrossRefPubMedGoogle Scholar
  17. 17.
    Gasser JA, Green JR, Novartis Pharma AG (2002) Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone 30:41SGoogle Scholar
  18. 18.
    Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG (1993) Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 3:255–260CrossRefPubMedGoogle Scholar
  19. 19.
    Neter J, Wasserman W, Ahitmore GA (1982) Applied statistics, 4 sub edn. Allyn & Bacon, BostonGoogle Scholar
  20. 20.
    Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 18:621–627CrossRefPubMedGoogle Scholar
  21. 21.
    Ferreri LF, Naito HK (1978) Effect of estrogens on rat serum cholesterol concentration: consideration of dose, type of estrogens and treatment duration. Endocrinology 102:1621–1627CrossRefPubMedGoogle Scholar
  22. 22.
    Brown MS, Glodstein JL (1980) The estradiol stimulated lipoprotein receptor of rat liver. J Biol Chem 254:10454–10471Google Scholar
  23. 23.
    Chao Y, Windler EE, Chen GC, Havel RJ (1979) Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl-estradiol. J Biol Chem 254:11360–11366PubMedGoogle Scholar
  24. 24.
    Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K (2004) Benefits of 2 years of intense EX on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS). Arch Intern Med 164:1084–1091CrossRefPubMedGoogle Scholar
  25. 25.
    Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599–604CrossRefPubMedGoogle Scholar
  26. 26.
    Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252–255PubMedGoogle Scholar
  27. 27.
    Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget’s bone disease treated with pamidronate. Bone 32:15–19CrossRefPubMedGoogle Scholar
  28. 28.
    Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657–1663PubMedGoogle Scholar
  29. 29.
    Tobert JA (1987) New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76:534–538PubMedGoogle Scholar
  30. 30.
    Thune I, Njolstad I, Lochen ML, Forde OH (1998) Physical activity improves the metabolic risk profiles in men and women: the Tromso Study. Arch Intern Med 158:1633–1640CrossRefPubMedGoogle Scholar
  31. 31.
    Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386–392CrossRefPubMedGoogle Scholar
  32. 32.
    Pedersen DK (2006) The anti-inflammatory effect of exercise: its role in diabetes and cardio-vascular disease control. Essays Biochem 42:105–117CrossRefPubMedGoogle Scholar
  33. 33.
    Corrado A, Santoro N, Cantatore FP (2007) Extra-skeletal effects of bisphosphonates. Joint Bone Spine 74:32–38CrossRefPubMedGoogle Scholar
  34. 34.
    Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, Monkkonen J (1999) Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 8:109–118CrossRefPubMedGoogle Scholar
  35. 35.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215CrossRefPubMedGoogle Scholar
  36. 36.
    Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM (2007) Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 41:290–296CrossRefPubMedGoogle Scholar

Copyright information

© AOCS 2010

Authors and Affiliations

  • E. Lespessailles
    • 1
  • C. Jaffré
    • 1
  • G. Y. Rochefort
    • 1
    Email author
  • E. Dolléans
    • 1
  • C. L. Benhamou
    • 1
  • D. Courteix
    • 1
  1. 1.UMR-S658 INSERM, CHR ORLEANS Porte MadeleineOrleans Cedex 1France

Personalised recommendations